Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Quanterix ( (QTRX) ) just unveiled an update.
On May 7, 2025, Quanterix‘s Board of Directors approved a cost-reduction plan to save $15 million in 2025, with annualized savings of $30 million. This includes a significant reduction in workforce, expected to be completed by the end of the second quarter of 2025. Additionally, Quanterix announced a strategic move to integrate its Simoa® ONE assay kits with over 20,000 flow cytometers globally, enhancing its market reach and reducing the need for new equipment purchases. The company also reported a net loss for the first quarter of 2025 but is implementing measures to achieve positive cash flow by 2026, including a merger with Akoya Biosciences, expected to close in June 2025.
The most recent analyst rating on (QTRX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
Quanterix’s overall stock score reflects a mixed outlook. Strong revenue growth and strategic acquisitions are positive, but persistent profitability issues and weak technical indicators weigh heavily. The company needs to improve operational efficiency to leverage its growth potential. Valuation concerns and market volatility further impact the score.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix Corporation is a company specializing in ultra-sensitive biomarker detection, which is instrumental in advancing scientific discovery. The company focuses on providing innovative solutions for researchers, particularly through its Simoa® ONE assay kits, which are now compatible with a wide range of existing flow cytometers, thereby expanding access to its technology.
Average Trading Volume: 729,436
Technical Sentiment Signal: Sell
Current Market Cap: $205M
For an in-depth examination of QTRX stock, go to TipRanks’ Stock Analysis page.